Study Highlights Benefits of Resuming Blood Thinners After GI Bleeds

Understanding Gastrointestinal Bleeding

Gastrointestinal (GI) bleeding is a prevalent medical issue, impacting roughly 150 individuals per 100,000 in both the United States and the United Kingdom, with a mortality rate ranging from 5% to 10%. Symptoms of GI bleeding can manifest visibly through blood in stool or vomit, or they can be subtle, presenting as lightheadedness, difficulty breathing, fainting, or chest and abdominal pain.

Challenges of Treating GI Bleeding in Patients on Antithrombotic Drugs

For patients on antithrombotic drugs, commonly referred to as blood thinners, experiencing a GI bleed poses significant treatment challenges. The need to manage the bleeding while minimizing the risk of ischemic events, such as heart attacks or strokes, is critical. Antithrombotic therapy plays a vital role in preventing and managing cardiovascular disease, constituting over 50% of prescriptions for affected patients. These include antiplatelet drugs (like aspirin and clopidogrel) and anticoagulants (such as warfarin), which work by inhibiting blood clot formation and growth.

When a GI bleed occurs, the standard practice is to halt the use of these medications, as continuing them can elevate the risk of rebleeding. This creates a dilemma for healthcare providers who must weigh the risks and benefits of resuming therapy against the need to treat the initial bleeding effectively. Currently, there are no definitive guidelines on how long to discontinue these medications or when to resume them after a GI bleed.

Research Findings on Resuming Antithrombotic Therapy

To explore this issue, researchers in Spain conducted a study involving 871 patients who experienced GI bleeding. They evaluated the rates of rebleeding, ischemic events, and mortality among patients receiving anticoagulant or antiplatelet therapy. The findings, published in *Alimentary Pharmacology and Therapeutics*, revealed that patients who resumed their anticoagulant or antiplatelet medications had a 39% lower risk of mortality or ischemic events, despite facing a higher risk of rebleeding over a two-year follow-up.

Notably, around 62% of patients who experienced rebleeding did so at the same site as the initial bleed. Furthermore, patients on anticoagulants faced approximately a 70% increased likelihood of rebleeding but about a 30% lower risk of ischemic events or death compared to those who did not resume therapy. In contrast, patients on antiplatelet medications exhibited a substantially reduced risk of death, with no significant difference in rebleeding or ischemic event risk.

The study also indicated that resuming antiplatelet or anticoagulant therapy seven or more days after discontinuation appears to be optimal, as this timeframe did not correlate with an increased risk of rebleeding, ischemic events, or death. In contrast, resuming therapy in less than seven days was associated with heightened rebleeding risks.

Conclusion and Implications

The authors of the study emphasize that their findings provide valuable insights for balancing the risks and benefits of managing patients on these commonly prescribed blood-thinning medications associated with increased GI bleeding risk.

Written by Bhavana Achary, Ph.D.

References

Sostres C, Marcén B, Laredo V, Ruiz L, Camo P, Carrera-Lasfuentes P, Lanas Á. Risk of rebleeding, vascular events and death after gastrointestinal bleeding in anticoagulant and/or antiplatelet users. Aliment Pharmacol Ther. 2019 Sep 4.

Kim BS, Li BT, Engel A, Samra JS, Clarke S, Norton ID, Li AE. Diagnosis of gastrointestinal bleeding: A practical guide for clinicians. World J Gastrointest Pathophysiol. 2014 Nov 15;5(4):467-78.

Fan P, Gao Y, Zheng M, Xu T, Schoenhagen P, Jin Z. Recent progress and market analysis of anticoagulant drugs. J Thorac Dis. 2018 Mar;10(3):2011-2025.

https://www.mayoclinic.org/diseases-conditions/gastrointestinal-bleeding/symptoms-causes/syc-20372729

Image by Frank Hull from Pixabay